Co-Authors
This is a "connection" page, showing publications co-authored by SHARON R HYMES and VICTOR PRIETO.
Connection Strength
0.568
-
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb; 44(2):158-176.
Score: 0.150
-
Annular plaques: An unusual manifestation of graft-versus-host disease. Dermatol Online J. 2012 Jun 15; 18(6):4.
Score: 0.110
-
Adult Henoch-sch?nlein purpura in a patient with myelodysplastic syndrome and a history of follicular lymphoma. Cutis. 2008 Feb; 81(2):131-7.
Score: 0.081
-
Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive review. J Cutan Pathol. 2021 Apr; 48(4):547-557.
Score: 0.049
-
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct; 45(10):786-790.
Score: 0.042
-
Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Arch Dermatol Res. 2016 Jul; 308(5):357-65.
Score: 0.036
-
BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 2016 Apr; 50:79-89.
Score: 0.035
-
Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol. 2013 Mar; 149(3):322-6.
Score: 0.029
-
Cutaneous leukocytoclastic vasculitis in a patient with myelodysplastic syndrome after therapy with the rapamycin analogue everolimus: case report and review of the literature. Leuk Lymphoma. 2006 May; 47(5):926-9.
Score: 0.018
-
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006 Jan; 12(1):31-47.
Score: 0.018